Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RSV-F Particle Vaccine · 1 trial · 1 indication
This primary outcome will be evaluated through an assessment of the following parameters: * Immediate AEs * Solicited AEs * All SAEs and SNMCs * Vital signs * Laboratory Assessments
| Arm | Type | Description |
|---|---|---|
| A: Dose 1 + adjuvant | EXPERIMENTAL | - |
| B: Dose 2 + adjuvant | EXPERIMENTAL | - |
| C: Dose 3 + adjuvant | EXPERIMENTAL | - |
| D: Dose 3 alone | EXPERIMENTAL | - |
| E: Placebo control | PLACEBO_COMPARATOR | - |
| F: Dose 4 alone | EXPERIMENTAL | - |
| G: Dose 4 +adjuvant | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RSV-F Particle Vaccine | BIOLOGICAL | Dose 1 + adjuvant / dose; Day 0 and Day 30 |
| Placebo | BIOLOGICAL | Placebo; Day 0 and Day 30 |
Inclusion Criteria: * Male or female aged 18 to 49 years inclusive * Ability to provide written informed consent to participate * Healthy, as determined by medical history, physical examination, vital signs, and clinical safety laboratory examinations at baseline * Females are required to fulfill o...
RSV-F Particle Vaccine is an investigational vaccine being developed for the prevention of Respiratory Syncytial Virus (RSV) infections. It is designed to elicit an immune response against the RSV fusion (F) protein. The vaccine is currently in clinical development and has not been approved for commercial use.
RSV-F Particle Vaccine is being developed by Novavax, Inc., a biotechnology company traded on the NASDAQ under the ticker symbol NVAX. The company is conducting clinical trials to evaluate the safety and immunogenicity of this investigational vaccine for Respiratory Syncytial Virus infections.
RSV-F Particle Vaccine is in Phase 1 clinical development. A Phase 1 trial has been completed, which evaluated the safety of the vaccine in healthy volunteers. The vaccine remains investigational and has not received regulatory approval for any indication.
RSV-F Particle Vaccine has been studied in one completed clinical trial, identified as NCT01290419. This Phase 1 study, titled 'Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine,' enrolled 150 participants in the United States. The trial was randomized, double-blind, and placebo-controlled.
No, RSV-F Particle Vaccine is not a monoclonal antibody. Although the modality is listed as a monoclonal antibody, the product is a vaccine designed to stimulate the immune system to produce antibodies against the RSV fusion protein. It is being developed as a preventive vaccine for Respiratory Syncytial Virus infections.
RSV-F Particle Vaccine targets the fusion (F) protein of the Respiratory Syncytial Virus (RSV). The F protein is essential for viral entry into host cells and is a key target for vaccine development. By presenting this protein to the immune system, the vaccine aims to generate protective antibodies against RSV.